Request Legal Help Now - Free


FDA Pulls Breast Cancer Indication for Avastin

. By
div itemprop="articleBody" class="article">Washington, DCAn FDA panel reviewing the efficacy of Roche’s blockbuster cancer drug Avastin in metastatic HER2 negative breast cancer has ruled to pull the indication. The vote took place Wednesday with the Advisory panel made up of cancer specialists voting unanimously to pull the indication. The panel voted three times, and each time the vote was unanimous, ruling that the data on Avastin in this particular group of breast cancer patients is not effective, and not necessarily safe, and therefore should not be approved for treatment.

In a report by the Associated Press for, Natalie Compagni-Portis, the lone patient representative on the FDA panel, said "I think we all wanted Avastin to succeed but the reality is that these studies did not bear out that hope.”

Notably, the panel’s vote is not binding, and FDA Commissioner Margaret Hamburg will make the final decision.

Avastin is currently approved for treatment of several cancers, and the FDA ruling will not affect these indications.


Avastin Legal Help

If you or a loved one have suffered losses in this case, please click the link below and your complaint will be sent to a drugs & medical lawyer who may evaluate your claim at no cost or obligation.


Please read our comment guidelines before posting.

Note: Your name will be published with your comment.

Your email will only be used if a response is needed.

Are you the defendant or a subject matter expert on this topic with an opposing viewpoint? We'd love to hear your comments here as well, or if you'd like to contact us for an interview please submit your details here.

Click to learn more about

Request Legal Help Now! - Free